WO2004056754A1 - A process for the preparation of racemic citalopram diol and/or s- or r- citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram - Google Patents
A process for the preparation of racemic citalopram diol and/or s- or r- citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram Download PDFInfo
- Publication number
- WO2004056754A1 WO2004056754A1 PCT/DK2003/000907 DK0300907W WO2004056754A1 WO 2004056754 A1 WO2004056754 A1 WO 2004056754A1 DK 0300907 W DK0300907 W DK 0300907W WO 2004056754 A1 WO2004056754 A1 WO 2004056754A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diol
- acid addition
- free base
- addition salt
- citalopram
- Prior art date
Links
- 229960001653 citalopram Drugs 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 68
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 150000002009 diols Chemical class 0.000 title claims description 73
- -1 citalopram diol Chemical class 0.000 title abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 251
- 150000003839 salts Chemical class 0.000 claims abstract description 232
- 239000012458 free base Substances 0.000 claims abstract description 202
- 239000000203 mixture Substances 0.000 claims abstract description 128
- 239000002904 solvent Substances 0.000 claims abstract description 64
- 239000002244 precipitate Substances 0.000 claims abstract description 56
- 238000000746 purification Methods 0.000 claims abstract description 21
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract description 13
- 238000000926 separation method Methods 0.000 claims abstract description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002955 isolation Methods 0.000 claims abstract description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 36
- 239000012452 mother liquor Substances 0.000 claims description 22
- 238000001556 precipitation Methods 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 150000003891 oxalate salts Chemical class 0.000 claims description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 229960004592 isopropanol Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 229960004132 diethyl ether Drugs 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 238000005191 phase separation Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 abstract description 3
- GNULRNVWXYXBQY-UHFFFAOYSA-N 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile Chemical compound C=1C=C(C#N)C=C(CO)C=1C(O)(CCCN(C)C)C1=CC=C(F)C=C1 GNULRNVWXYXBQY-UHFFFAOYSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 239000012071 phase Substances 0.000 description 29
- 239000007787 solid Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000047 product Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 8
- 229960004341 escitalopram Drugs 0.000 description 8
- 238000007429 general method Methods 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000000638 solvent extraction Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012485 toluene extract Substances 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- GNULRNVWXYXBQY-HXUWFJFHSA-N 4-[(1r)-4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile Chemical compound C1([C@](O)(CCCN(C)C)C=2C(=CC(=CC=2)C#N)CO)=CC=C(F)C=C1 GNULRNVWXYXBQY-HXUWFJFHSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N CN(C)CCCC1(c(cc2)ccc2F)OCc2cc(C#N)ccc12 Chemical compound CN(C)CCCC1(c(cc2)ccc2F)OCc2cc(C#N)ccc12 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/32—Separation; Purification; Stabilisation; Use of additives
- C07C253/34—Separation; Purification
Definitions
- the invention relates to a process for the preparation of racemic citalopram diol and R- or S-citalopram diol by separating an initial non-racemic mixture of the compounds R- and S-citalopram diol (R- and S-4-[4-(dimethylamino)-l-(4'-fluorophenyl)-l- hydiOxybutyl]-3-(hydroxymethyl)-benzonitrile) into a fraction of racemic citalopram diol and a fraction being enriched with S-diol or R-diol.
- the invention also relates to the use of such isolated citalopram diols for the formation of the corresponding racemic citalopram and/or S- or R-citalopram to be comprised in a pharmaceutical composition.
- Citalopram is a well-known antidepressant drug that has now been on the market for some years and has the following structure:
- Citalopram may be prepared by ring closure of 4-[4-(dimethylamino)-l-(4'- fluorophenyl)- 1 -hydroxybutyl]-3-(hydroxymethyl)-benzonitrile (racemic citalopram diol) as described in US patent No. 4,650,884.
- the product citalopram is a racemic mixture of the R- and S-enantiomers.
- S-enantiomer of citalopram is a valuable antidepressant of the selective serotonin reuptake inhibitor (SSRI) type.
- Escitalopram may be prepared by ring closure of S-4-[4-(dimethylamino)-l-(4'-fluorophenyl)-l-hydroxybutyl]-3- (hydroxymethyl)-benzonitrile (S-diol) with retention of configuration as described in EP Bl 347 066.
- the amount of R-citalopram compared to S-citalopram in the product escitalopram should be less than 3%.
- racemic citalopram and escitalopram with the above-mentioned enantiomeric purity are required for the preparation of pharmaceutical compositions and that racemic citalopram and escitalopram products may be prepared by ring closure of the RS-diol and R-diol and/or S-diol.
- methods for the preparation of products of racemic diol and S-diol being correspondingly enantiomerically pure are required.
- the present invention provides a process for the separation of an initial non-racemic mixture of R- and S-4-[4-(dimethylamino)-l-(4'-fluorophenyl)-l- hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of one of the enantiomers into a fraction being enriched with S-diol or R-diol and a fraction comprising RS-diol, wherein the ratio of R-diol:S-diol is equal to 1 : 1 or closer to 1 : 1 than in the initial mixture of R- and S-diol.
- the process of the invention is important and very useful, in particular because it provides a convenient, cheap and efficient way to transform a mixture of R- and S- diols which does not meet the above requirements as regards enantiomeric purity into two valuable products, RS-diol and S-diol (or R-diol), which meet the above requirements as regards enantiomeric purity.
- the invention provides a convenient, cheap and efficient method for making an intermediate to be used in the manufacturing of citalopram and escitalopram.
- the process for the production of racemic citalopram and escitalopram meeting the requirements of the respective marketing approvals has become more rational and more economical as regards the simplicity of the process and the utilisation of reagents and resources.
- the present invention relates to a process for the preparation of racemic diol free base and/or acid addition salt and/or R- or S-diol free base and/or an acid addition salt comprising a separation of an initial non-racemic mixture of R- and S-diol free base and/or acid addition salt with more than 50% of one of the enantiomers into a fraction being enriched with S-diol or R-diol free base and or acid addition salt and a fraction comprising RS-diol free base and/or acid addition salt wherein the ratio of R-diol:S- diol is equal to 1:1 or closer to 1 : 1 than in the initial mixture of R- and S-diol wherein i) RS-diol free base and/or acid addition salt is precipitated from a solution of the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt; or
- R- or S-diol free base and/or acid addition salt is dissolved into a solvent from the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt in said solvent, leaving a residue comprising RS-diol free base and/or acid addition salt;
- steps i) and ii) are optionally repeated until a crystalline residue/precipitate is obtained and the crystalline residue/precipitate is optionally recrystallised one or more times to form racemic diol;
- the final solution phase is optionally subjected to further purification and S-diol or R-diol free base and/or acid addition salt is isolated from the final solution phase;
- the free bases of the diols obtained are optionally converted to acid addition salts thereof or acid addition salts of the diols obtained are optionally converted to other acid addition salts or acid addition salts of the diols obtained are optionally converted to the corresponding free bases.
- the RS-diol free base and/or acid addition salt obtained gives rise to the final solution phase being enriched with either the S- or R-diol free base and/or acid addition salt.
- the surplus of R- or S-diol free base and/or acid addition salt may then be isolated from the final solution phase as described below.
- the invention relates to a process for the preparation of racemic diol free base and/or acid addition salt using the process described above.
- the invention relates to a process for the preparation of S-diol (or R-diol) free base and/or an acid addition salt using the process described above.
- the invention relates to the use of the prepared racemic diol free base and/or acid addition salt and/or S-diol (or R-diol) free base and/or an acid addition salt for the preparation of racemic citalopram and/or S- citalopram (or R-citalopram) free base and/or acid addition salt using the process described below.
- S-diol and “S-citalopram diol” mean S- 4- [4-(dimethylamino)- 1 -(4-fluorophenyl)- 1 -hydroxybutyl] -3 -(hydroxymethyl) benzonitrile.
- R-diol and “R-citalopram diol” mean R- 4- [4-(dimethylamino)- 1 -(4-fluorophenyl)- 1 -hydroxybutyl] -3 -(hydroxymethyl) benzonitrile.
- RS-diol means a mixture of R- and S-diol such as a 0.5:1.5 or 0.9:1.1 or 0.95:1.05 or 0.98:1.02 or 0.99:1.01 mixture of R- and S- diol and preferably a mixture with a 1:1 ratio of the R- and S-diol.
- diol enantiomer and “diol isomer” mean either S- or R-diol.
- racemic diol means a 1 :1 mixture of the R- and S-diols.
- non-racemic mixtures of diols means mixtures which contain R- and S-diols in a ratio other than 1:1.
- citalopram enantiomer and “citalopram isomer” mean either S- or R-citalopram.
- racemic citalopram means a 1 : 1 mixture of R- and S-citalopram.
- non-racemic citalopram means mixtures which contain R- and S-citalopram in a ratio other than 1:1.
- precipitation means forming a precipitate, in the form of crystals, an amorphous solid or an oil or mixtures thereof, from a solution of the initial non-racemic mixture of R- and S-diol in a solvent.
- a precipitate may be an oil, an amorphous solid or crystals or mixtures thereof.
- residue refers to the residue remaining after dissolving R- or S-diol into a solvent from an initial non-racemic mixture of R- or S- diols.
- the residue may be in the form of crystals, an amorphous solid or an oil or mixtures thereof.
- reduct/precipitate refers to either a precipitate or a residue as defined above.
- mother liquor means the solvent remaining after removal or separation from the precipitate.
- the term "organic and/or aqueous phase resulting from the selective dissolution of R- or S-diol” refers to the phase wherein R- or S-diol is dissolved from an initial non-racemic mixture of R- or S-diols.
- final solution phase refers to a mother liquor or an organic and/or aqueous phase resulting from the selective dissolution of R- or S-diol as defined above.
- This new process involves the separation of an initial non-racemic mixture of R- and S-diol free base and/or acid addition salt into a fraction of racemic diol free base and/or acid addition salt and a fraction of R- or S-diol free base and/or acid addition salt.
- the fraction of racemic diol free base and/or acid addition salt is precipitated as an oil, an amorphous solid or in crystalline form or mixtures thereof from a solvent, and the R- or S-diol free base and/or acid addition salt is isolated from the final solution phase.
- racemic citalopram free base and/or acid addition salt and R- or S-citalopram free base and/or acid addition salt may be formed from the corresponding racemic diol free base and/or acid addition salt and R- or S-diol free base and/or acid addition salt by ring closure.
- the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt is separated into a fraction being enriched with S-diol or R-diol free base and/or acid addition salt and a fraction comprising RS-diol free base and/or acid addition salt wherein the ratio of R-diol:S- diol is equal to 1 : 1 or closer to 1 : 1 than in the initial mixture of R- and S-diol by mixing the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt with a solvent and allowing preferentially the R- or S-diol free base and/or acid addition salt to dissolve in the solvent followed by separation of the undissolved RS- diol free base and/or acid addition salt residue from the organic and/or aqueous phase resulting from the selective dissolution of R- or S-diol free base and/or acid addition salt and isolation of R- and
- the solvent used according to this embodiment of the invention is any solvent which allow preferentially the R-or S-diol free base and/or acid addition salt to dissolve leaving a mixture of RS-diol free base and/or an acid addition salt wherein the ratio of R-diol:S-diol is equal to 1:1 or closer to 1:1 than in the initial mixture of R- and S-diol as a residue.
- Useful solvents are solvents such as those mentioned for the precipitation of RS-diol free base and/or RS-diol acid addition salts.
- the initial non-racemic mixture of R- and S- diol free base and/or acid addition salt used in the process of the invention may be an oil, an amorphous solid or in crystalline form; or mixtures thereof.
- the residue/precipitate formed in step i) may be an oil, an amorphous solid or in crystalline form; or a mixture thereof.
- the residue/precipitate formed in step i) is preferably in crystalline form.
- the initial non-racemic mixture of R- and S- diol free base and or acid addition salt used in the process of the invention contains more than 50% of S-diol, or more preferred more than 70% of S-diol or most preferred more than 90% of S-diol.
- the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt used in the process of the invention contains less than 99.9% of S-diol, such as less than 99.5% of S-diol, or less than 99% S-diol, or less than 98% of S-diol.
- the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt may contain 50%-98% of S-diol, or 50%-99% of S-diol, or 50%-99.5% of S-diol, or 50%-99.9% of S-diol, or 70%-98% of S-diol, or 70%-99% of S-diol, or 70%-99.5% of S-diol, or 70%-99.9% of S-diol, or 90%-98% of S-diol, or 90%-99% of S-diol, or 90%-99.5% of S-diol, or 90%-99.9% of S-diol.
- the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt used in the process of the invention contains more than 50% of R-diol, or more preferred more than 70% of R-diol or most preferred more than 90% of R-diol.
- the initial non-racemic mixture of R- and S-diol free base andor acid addition salt used in the process of the invention contains less than 99.9% of R-diol, such as less than 99.5% of R-diol, or less than 99% R-diol, or less than 98% of R-diol.
- the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt may contain 50%-98% of R-diol, or 50%-99% of R-diol, or 50%-99.5% of R-diol, or 50%-99.9% of R-diol, or 70%-98% of R-diol, or 70%-99% of R-diol, or 70%-99.5% of R-diol, or 70%-99.9% of R-diol, or 90%-98% of R-diol, or 90%-99% of R-diol, or 90%-99.5% of R-diol, or 90%-99.9% of R-diol.
- the process may be repeated until a racemic mixture of R- and S-diols is obtained and/or until the desired degree of enantiomeric purity of the R- or S-diol is obtained.
- the RS-diol of the residue/precipitate is in the form of a free base and/or an acid addition salt; and independently thereof the R- or S-diol of the final solution phase is in the form of a free base and/or an acid addition salt. Accordingly, when the RS-diol comprised in the residue/precipitate is in the form of a free base, then the R- or S-diol comprised in the final solution phase, may be in the form of a free base, an acid addition salt or a mixture of a free base and an acid addition salt.
- the R- or S-diol comprised in the final solution phase may be in the form of a free base, an acid addition salt or a mixture of a free base and acid addition salt.
- the R- or S-diol comprised in the final solution phase may be in the form of a free base, an acid addition salt or a mixture of a free base and acid addition salt.
- the initial non-racemic mixture of R- and S- diol used in the process of the invention may be present as the free base, as salts, or as a mixture of free bases and salts.
- the free bases of the diols obtained are optionally converted to acid addition salts thereof or acid addition salts of the diols obtained are optionally converted to other acid addition salts or acid addition salts of the diols obtained are optionally converted to the corresponding free bases by methods known to those skilled in the art.
- Precipitation of the RS-diol free base may be carried out by obtaining or dissolving the non-racemic mixture of R- and S-diol free base and/or acid addition salt in a suitable solvent, optionally by applying heat, and then allowing the solution to cool, or by cooling to below ambient temperature. The precipitate is then separated from the mother liquor, preferably by filtration or decanting.
- a residue of RS-diol free base may be formed by selective dissolution of R- or S-diol free base and/or acid addition salt into a solvent from the initial non-racemic mixture of R- and S-diols free base and/or acid addition salt in said solvent.
- the residue is then separated from the organic and/or aqueous phase resulting from the selective dissolution of R- or S-diol.
- racemic citalopram free base may be formed from the racemic diol free base by ring closure.
- the free base of racemic citalopram may optionally be converted to an acid addition salt thereof, preferably the hydrobromide salt.
- steps i) and ii) may be repeated until a crystalline product is obtained.
- the crystals obtained are optionally recrystallised one or more times to form racemic diol free base.
- Racemic citalopram free base may be formed from the racemic diol free base by ring closure.
- the free base of racemic citalopram is optionally converted to an acid addition salt thereof, preferably the hydrobromide salt.
- the RS-diol free base prepared according to the invention is optionally converted to acid addition salts thereof.
- An oily phase separated from the final solution phase is optionally subjected to conventional purification processes.
- the RS-diol free base prepared according to the invention may contain a minor excess of the S-diol (or R-diol). It may thus be necessary to repeat steps i) and ii) (in particular crystallisation) of the RS-diol free base one or more times in order to obtain racemic diol.
- the final solution phases may be pooled together and the diol enantiomer contained herein may be isolated as described below.
- Suitable solvents for obtaining the residue/precipitate comprising the RS-diol free base are apolar solvents for example alkanes, such as heptane or hexane, aromatic hydrocarbons such as toluene, benzene and xylene, polar solvents such as acetonitrile, alcohols such as methanol and iso-propylalcohol or ketones such as methyl isobutyl ketone; or mixtures thereof.
- alkanes such as heptane or hexane
- aromatic hydrocarbons such as toluene, benzene and xylene
- polar solvents such as acetonitrile
- alcohols such as methanol and iso-propylalcohol or ketones such as methyl isobutyl ketone; or mixtures thereof.
- a free base of the RS-diol is obtained in step i), preferably in crystalline form.
- crystallisation may be initiated by seeding with racemic crystalline diol free base.
- the precipitation of RS-diol acid addition salt may be carried out by obtaining or dissolving the non-racemic mixture of R- and S-diol free base or acid addition salt in a suitable solvent, if necessary by applying heat, and adding an acid, for example as a solid, a liquid, in a solution or as a gas.
- the acid used for the precipitation of a RS-diol acid addition salt is an acid which precipitates a mixture of R- and S-enantiomers and leaves the mother liquor enriched with either the R- or S-diol enantiomer of the diol as the free base or an acid addition salt.
- the acid used for the precipitation of a RS-diol acid addition salt may be:
- a residue of RS-diol acid addition salt may be formed by selective dissolution of R- or S-diol free base and/or acid addition salt into a solvent from the initial non-racemic mixture of R- and S-diols free base and/or acid addition salt in said solvent, if necessary by adding an acid, for example as a solid, a liquid, in a solution or as a gas; or mixtures thereof.
- the acidic part of a RS-diol acid addition salt of the residue formed in step i) is an acid, which allows the selective dissolution of either R- or S-diol free base and/or acid addition salt and leaves the undissolved material enriched with the RS-diol acid addition salt.
- the acid used for forming the RS-diol acid addition salt of the residue may be: • present in the solvent before the initial non-racemic mixture of R- and S- diol free base and/or acid addition salt is mixed with the solvent; and/or
- Suitable acids for the formation of a residue/precipitate of RS-diol acid addition salt from an initial non-racemic mixture of R- and S-diol free base and/or acid addition salt are inorganic acids such as hydrochloric acid, hydrobromic acid and sulphuric acid or organic acids such as oxalic acid, j ⁇ -toluenesulfonic acid, methanesulfonic acid and acetic acid. Hydrobromic acid, hydrochloric acid and oxalic acid are preferred acids. When these acids are used, a hydrobromide salt, hydrochloride salt or oxalate salt of the RS-diol is formed, preferably in crystalline form. Suitably, up to 10 equivalents of acid is used. Accordingly:
- 0.2-10 mol of acid may be used, such as 0.2-0.4 mol, or 0.4-0.6 mol, or 0.9-1.1 mol or 1.8-2.2 mol of acid is used for each mol of S- and R-diol comprised in the initial non-racemic mixture of R- and S-diol free base and/or acid addition salt; and/or
- salts such as NaCl may be added to the solution before, during or after the RS-diol acid addition salt is obtained in step i).
- salts such as NaCl may be added to the solution before, during or after the RS-diol acid addition salt is obtained in step i).
- Suitable solvents for the formation of a residue/precipitate of RS-diol acid addition salt from an initial non-racemic mixture of R- and S-diol free base and/or acid addition salt are polar and apolar solvents such as toluene, ethyl acetate, diethylether, THF, alcohols such as ⁇ o-propylalcohol, acetonitrile, and ketones such as acetone and methyl isobutyl ketone, and water.
- the crystals are separated from the final solution phase, preferably by filtration or decanting.
- the crystals are optionally recrystallised by dissolving the crystals in a solvent, preferably by heating, and allowing the solution to cool, or by cooling to below ambient temperature.
- Racemic citalopram may be formed from the crystalline racemic diol acid addition salt by ring closure.
- the racemic citalopram may be converted to a pharmaceutically acceptable salt thereof, preferably the HBr salt.
- step i) If the residue/precipitate formed in step i) is not crystalline, but amorphous or an oil, or mixtures thereof, steps i) and ii) may be repeated until a crystalline product is obtained.
- the crystals obtained are optionally recrystallised one or more times as described above.
- Racemic citalopram may be formed from the crystalline racemic diol acid addition salt by ring closure.
- the racemic citalopram may be converted into a pharmaceutically acceptable salt thereof, preferably the HBr salt.
- An oily phase separated from the final solution phase is optionally subjected to conventional purification processes.
- the RS-diol acid addition salt prepared according to the invention may contain a minor excess of the S-diol (or R-diol). It may thus be necessary to repeat precipitation (in particular crystallisation) of the RS-diol acid addition salt one or more times in order to obtain a racemic mixture.
- the final solution phase may be pooled together and the diol enantiomer contained herein may be isolated as described below.
- crystallisation of the RS-diol acid addition salt may be initiated by seeding with the racemic crystalline diol acid addition salt.
- the RS-diol acid addition salt prepared according to the invention is optionally converted into other acid addition salts or the corresponding free base.
- a free base of the RS-diol or a hydrochloride salt, hydrobromide salt or oxalate salt of the RS-diol is obtained, preferably in crystalline form in steps i), iia) and iib).
- the final solution phase, extracts thereof, or a phase enriched with R- or S-diol free base and/or acid addition salt may be subjected to conventional purification processes (such as treatment with active carbon, chromatography etc.) before evaporation of the solvent, and/or it may be subjected to one or more further precipitations of RS-diol free base or RS-diol acid addition salt according to the invention, in order to improve the enantiomeric purity of the diol enantiomer product.
- the R- or S-diol free base and/or acid addition salt may be isolated from the final solution phase using conventional procedures such as evaporation of the solvent, or in case the final solution phase is acidic by basification followed by separation of phases or by extraction of R- or S-diol free base and/or acid addition salt followed by evaporation of the solvent.
- the final solution phase, extracts thereof, or a phase enriched with R- or S-diol free base and/or acid addition salt may be subjected to conventional purification processes (such as treatment with active carbon, chromatography etc.) before the isolation from the R- or S-diol free base and/or acid addition salts.
- R- or S-diol may be precipitated as a phosphate salt or an oxalate salt by methods known to those skilled in the art.
- the enantiomeric purity (the ratio between the wanted isomer and the sum of both isomers) of the S- or R-diol free base and/or acid addition salt left in the final solution phase may be as high as 97-98% or even higher (i.e. better) depending on the specific conditions used.
- the S-diol (or R-diol) free base and/or acid addition salt prepared according to the invention may contain a minor amount of the R-diol (or S-diol) free base and/or acid addition salt.
- this minor amount may be less than 3%, or more preferred less than 2%, or most preferred less than 1% (the ratio between the isomer contained in a minor amount and the sum of both isomers).
- the R-or S-diol free base and/or acid addition salt may be purified and isolated from said solvent or final solution phase as described above.
- R-diol free base or acid addition salt is obtained.
- S-diol free base or acid addition salt is obtained.
- R- or S-diol free base When R- or S-diol free base is obtained, it is optionally converted to acid addition salts thereof. When R- or S-diol acid addition salt is obtained, it is optionally converted to other acid addition salts or to the corresponding free base.
- Enantiomerically-pure R- or S-diol free base and/or acid addition salt may be mixed with a non-racemic mixture of R- and S-diol free base and/or acid addition salt to obtain racemic diol free base and/or acid addition salt. Racemic diol free base and/or acid addition salt may then be obtained by one or more precipitations of racemic diol free base and/or an acid addition salt thereof, followed by recrystallisation as described above.
- R- or S-citalopram free base and/or acid addition salt may be formed from the corresponding R- or S-diol free base and/or acid addition salt by ring closure with retention of configuration.
- S-citalopram (or R-citalopram) free base and/or acid addition salt may optionally be converted to an acid addition salt thereof, preferably the oxalate salt and optionally recrystallised.
- Ring closure of the R- or S-diol free base and/or acid addition salt may be performed via a labile ester intermediate, e.g. in the presence of tosyl-chloride, in a basic environment, as described in EP-B 1-347 066. Then, the ring closing reaction proceeds with retention of the stereochemistry. R- or S-citalopram free base and/or acid addition salt of an enantiomeric purity substantially equal to the starting diol is then obtained.
- Ring closure of the obtained racemic diol free base and/or acid addition salt may be performed in an acidic environment, as described in US 4,650,884, or via a labile ester as described above. Thereby, racemic citalopram is obtained.
- the thus-obtained enantiomerically-pure R- or S-citalopram free base and/or acid addition salt may be mixed with a non-racemic mixture of R- and S-citalopram free base and/or acid addition salt to obtain racemic citalopram free base and/or acid addition salt.
- Racemic citalopram free base and/or acid addition salt may then be obtained by one or more precipitations of citalopram free base or an acid addition salt thereof, followed by recrystallisation as described above.
- One particular embodiment of the invention relates to a process for the preparation of racemic diol free base or an acid addition salt thereof and/or R- or S-diol as the free base or an acid addition salt thereof by the separation of an initial non-racemic mixture of R- and S-diol with more than 50% of one of the enantiomers into a fraction being enriched with S-diol or R-diol and a fraction consisting of RS-diol wherein the ratio of R-diol:S-diol is equal to 1:1 or closer to 1:1 than in the initial mixture of R- and S-diol wherein
- RS-diol is precipitated from a solvent as the free base or as an acid addition salt thereof;
- steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is optionally recrystallised one or more times to form racemic diol;
- the mother liquor is optionally subjected to further purification and S- diol or R-diol is isolated from the mother liquor;
- the free bases of the diols obtained are optionally converted to acid addition salts thereof or acid addition salts of the diols obtained are optionally converted to other acid addition salts or acid addition salts of the diols obtained are optionally converted to the corresponding free bases.
- Another particular embodiment of the invention relates to a process for the preparation of racemic diol free base or an acid addition salt thereof and/or R- or S- diol as the free base or an acid addition salt thereof by the separation of an initial non- racemic mixture of R- and S-diol with more than 50% of one of the enantiomers into a fraction being enriched with S-diol or R-diol and a fraction consisting of RS-diol wherein the ratio of R-diol:S-diol is equal to 1:1 or closer to 1:1 than in the initial mixture of R- and S-diol wherein
- RS-diol is precipitated from a solvent as the free base or as an acid addition salt thereof;
- R- or S-diol is dissolved into a solvent from the initial non-racemic mixture of R- or S-diols as the free base or as an acid addition salt thereof in said solvent, leaving a residue;
- steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is optionally recrystallised one or more times to form racemic diol;
- the mother liquor is optionally subjected to further purification and S- diol or R-diol is isolated from the mother liquor;
- the free bases of the diols obtained are optionally converted to acid addition salts thereof or acid addition salts of the diols obtained are optionally converted to other acid addition salts or acid addition salts of the diols obtained are optionally converted to the corresponding free bases.
- optical purities were measured by Chiral SCFC (super critical fluid chromatography) HPLC.
- optical purity is measured by Chiral HPLC.
- the aqueous layer was washed once more with toluene or ether, and the combined organic extracts were dried over magnesium sulfate and evaporated under reduced pressure to give mainly a solid or an oil. See table for details. Recovery of material was virtually quantitative, with the expected partitioning of weight between the respective samples.
- aqueous layer was washed once more with ether, and the combined ether extracts were dried over magnesium sulfate and evaporated under reduced pressure to give mainly a solid or an oil. See table for details. Recovery of material was virtually quantitative, with the expected partitioning of weight between the respective samples.
- the aqueous layer was washed once more with toluene, and the combined toluene extracts were dried over magnesium sulfate and evaporated under reduced pressure to give mainly a solid or an oil. See table for details. Recovery of material was virtually quantitative, with the expected partitioning of weight between the respective samples.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05006783A MXPA05006783A (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or s-. |
NZ540653A NZ540653A (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or S- or R- citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
CA2511143A CA2511143C (en) | 2002-12-23 | 2003-12-18 | Preparation of racemic and/or s- or r-citalopram diols and their use for the preparation racemic and/or s- or r-citalopram |
MEP-2008-57A ME00034B (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or s-or r-citalopram diols and use of such diols for the preparation of racemic citalopram, rcitalopram and/or s-citalopram |
DK03767476.9T DK1581483T3 (en) | 2002-12-23 | 2003-12-18 | PROCEDURE FOR PREPARING RACEMIC CITALOPRAM DIOL AND / OR S- OR R-CITALOPRAM DIOLS AND USING THEREOF FOR THE PREPARATION OF RACEMIC CITALOPRAM, R-CITALOPRAM AND / OR S-CITALOPRAM |
EP03767476A EP1581483B1 (en) | 2002-12-23 | 2003-12-18 | A PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM DIOL AND/OR i S- /i OR i R- /i CITALOPRAM DIOLS AND THE USE OF SUCH DIOLS FOR THE PREPARATION OF RACEMIC CITALOPRAM, i R- /i CITALOPRAM AND/OR i S- /i CITALOPRAM |
ES03767476T ES2385975T3 (en) | 2002-12-23 | 2003-12-18 | Procedure for the preparation of racemic citalopram diol and / or S-O R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and / or S-citalopram |
BR0317629-0A BR0317629A (en) | 2002-12-23 | 2003-12-18 | Process for the preparation of acid addition salt and / or racemic diol free base and / or acid addition salt and / or r- or s-diol free base, use of acid addition salt and / or rs-diol free base and / or acid addition salt and / or s-diol free base and / or acid addition salt and / or r-diol free base, and method for preparing acid addition salt and / or free base of citalopram and / or acid addition salt and / or free base of s-citalopram and / or acid addition salt and / or free base of r-citalopram |
YU20050488A RS52152B (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
AU2003291960A AU2003291960B2 (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or S- or R- citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
SI200332174T SI1581483T1 (en) | 2002-12-23 | 2003-12-18 | A PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM DIOL AND/OR i S- /i OR i R- /i CITALOPRAM DIOLS AND THE USE OF SUCH DIOLS FOR THE PREPARATION OF RACEMIC CITALOPRAM, i R- /i CITALOPRAM AND/OR i S- /i CITALOPRAM |
US10/540,300 US7390913B2 (en) | 2002-12-23 | 2003-12-18 | Process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram |
EA200501042A EA009061B1 (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopramdiol and/or s- or r citalopramdiols and a process for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
JP2004561086A JP4505335B2 (en) | 2002-12-23 | 2003-12-18 | A process for producing racemic citalopramdiol and / or S- or R-citalopramdiol, and a process for using said diol to produce racemic citalopram, R-citalopram and / or S-citalopram. |
IS7886A IS2862B (en) | 2002-12-23 | 2005-06-09 | Method for the preparation of racemic citalopramdiol and / or S- or R-citalopramdiols and the use of such diols for the production of racemic citalopram, R-citalopram and / or S-citalopram |
IL169330A IL169330A0 (en) | 2002-12-23 | 2005-06-21 | A process for the preparation of racemic citalopram diol and/or s- or r- citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
NO20053613A NO331181B1 (en) | 2002-12-23 | 2005-07-25 | Process for the preparation of racemic citalopram diol and / or S or R citalopram diols |
HK06108212A HK1087994A1 (en) | 2002-12-23 | 2006-07-24 | A process for the preparation of racemic citalopram diol and/or s- or r- citalopram diols and the use of sush diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43611702P | 2002-12-23 | 2002-12-23 | |
DKPA200202004 | 2002-12-23 | ||
US60/436,117 | 2002-12-23 | ||
DKPA200202004 | 2002-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004056754A1 true WO2004056754A1 (en) | 2004-07-08 |
Family
ID=32683721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2003/000907 WO2004056754A1 (en) | 2002-12-23 | 2003-12-18 | A process for the preparation of racemic citalopram diol and/or s- or r- citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram |
Country Status (14)
Country | Link |
---|---|
US (1) | US7390913B2 (en) |
EP (2) | EP2363389A1 (en) |
JP (1) | JP4505335B2 (en) |
AU (1) | AU2003291960B2 (en) |
CA (1) | CA2511143C (en) |
CY (1) | CY1112937T1 (en) |
HK (1) | HK1087994A1 (en) |
IL (1) | IL169330A0 (en) |
IS (1) | IS2862B (en) |
MX (1) | MXPA05006783A (en) |
NO (1) | NO331181B1 (en) |
NZ (1) | NZ540653A (en) |
PL (1) | PL207847B1 (en) |
WO (1) | WO2004056754A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006037714A3 (en) * | 2004-10-01 | 2006-07-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
EP1700851A1 (en) * | 2003-12-19 | 2006-09-13 | Hangzhou Minsheng Pharm. Co., Ltd. | Crystalline citalopram diol intermediate alkali |
WO2007012954A1 (en) * | 2005-07-27 | 2007-02-01 | Aurobindo Pharma Limited | An improved process for the preparation of escitalopram |
WO2009033488A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S | Method for manufacture of escitalopram |
US8022232B2 (en) | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
US9297416B2 (en) | 2011-04-29 | 2016-03-29 | Saint-Gobain Performance Plastics Pampus Gmbh | Maintenance-free slide bearing with FEP or PFA in the adhesive layer |
DK201500520A1 (en) * | 2015-08-31 | 2016-09-19 | H Lundbeck As | Crystalline forms of (R)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile free base and (S)-4-[4-(dimethylamino)-1-(4'-fluoro-phenyl)-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile free base and of racemic 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-hydroxybutyl]-3-(hydroxyl-methyl)-benzonitrile toluene hemisolvate |
US9782956B2 (en) | 2011-12-28 | 2017-10-10 | Saint-Gobain Performance Plastics Corporation | Polymer coating on substrates using thermal spray techniques |
US9803690B2 (en) | 2012-09-28 | 2017-10-31 | Saint-Gobain Performance Plastics Pampus Gmbh | Maintenance-free slide bearing with a combined adhesive sliding layer |
US9981284B2 (en) | 2011-12-28 | 2018-05-29 | Saint-Gobain Performance Plastics Corporation | Method of forming a laminate |
US10113588B2 (en) | 2012-06-29 | 2018-10-30 | Saint-Gobain Performance Plastics Pampus Gmbh | Slide bearing comprising a primer system as adhesion promoter |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI339651B (en) * | 2004-02-12 | 2011-04-01 | Lundbeck & Co As H | Method for the separation of intermediates which may be used for the preparation of escitalopram |
GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0347066A1 (en) * | 1988-06-14 | 1989-12-20 | H. Lundbeck A/S | New enantiomers and their isolation |
WO2003000672A1 (en) * | 2001-06-25 | 2003-01-03 | H. Lundbeck A/S | Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
JP2001123239A (en) | 1999-10-21 | 2001-05-08 | Daiki Aluminium Industry Co Ltd | High strength aluminum alloy for casting and aluminum alloy casting |
AR034759A1 (en) | 2001-07-13 | 2004-03-17 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF ESCITALOPRAM |
-
2003
- 2003-12-18 CA CA2511143A patent/CA2511143C/en not_active Expired - Fee Related
- 2003-12-18 EP EP11164841A patent/EP2363389A1/en not_active Withdrawn
- 2003-12-18 AU AU2003291960A patent/AU2003291960B2/en not_active Ceased
- 2003-12-18 WO PCT/DK2003/000907 patent/WO2004056754A1/en active Application Filing
- 2003-12-18 PL PL377525A patent/PL207847B1/en unknown
- 2003-12-18 MX MXPA05006783A patent/MXPA05006783A/en active IP Right Grant
- 2003-12-18 US US10/540,300 patent/US7390913B2/en not_active Expired - Fee Related
- 2003-12-18 JP JP2004561086A patent/JP4505335B2/en not_active Expired - Lifetime
- 2003-12-18 EP EP03767476A patent/EP1581483B1/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ540653A patent/NZ540653A/en unknown
-
2005
- 2005-06-09 IS IS7886A patent/IS2862B/en unknown
- 2005-06-21 IL IL169330A patent/IL169330A0/en unknown
- 2005-07-25 NO NO20053613A patent/NO331181B1/en not_active IP Right Cessation
-
2006
- 2006-07-24 HK HK06108212A patent/HK1087994A1/en not_active IP Right Cessation
-
2012
- 2012-07-04 CY CY20121100594T patent/CY1112937T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0347066A1 (en) * | 1988-06-14 | 1989-12-20 | H. Lundbeck A/S | New enantiomers and their isolation |
WO2003000672A1 (en) * | 2001-06-25 | 2003-01-03 | H. Lundbeck A/S | Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1700851A1 (en) * | 2003-12-19 | 2006-09-13 | Hangzhou Minsheng Pharm. Co., Ltd. | Crystalline citalopram diol intermediate alkali |
EP1700851A4 (en) * | 2003-12-19 | 2008-09-17 | Hangzhou Minsheng Pharm Co Ltd | Crystalline citalopram diol intermediate alkali |
US7435838B2 (en) * | 2003-12-19 | 2008-10-14 | Hangzhou Minsheng Pharmaceutical Co. Ltd. | Crystalline citalopram diol intermediate alkali |
WO2006037714A3 (en) * | 2004-10-01 | 2006-07-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
JP2008514670A (en) * | 2004-10-01 | 2008-05-08 | エイドルケム テクノロジー エスピーエー | Preparation method of citalopram and escitalopram |
US7482477B2 (en) | 2004-10-01 | 2009-01-27 | Adorkem Technology Spa | Process for the preparation of citalopram and escitalopram |
WO2007012954A1 (en) * | 2005-07-27 | 2007-02-01 | Aurobindo Pharma Limited | An improved process for the preparation of escitalopram |
DE102008046530A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S, Valby | Process for the preparation of escitalopram |
WO2009033488A1 (en) | 2007-09-11 | 2009-03-19 | H. Lundbeck A/S | Method for manufacture of escitalopram |
US8022232B2 (en) | 2007-09-11 | 2011-09-20 | H. Lundbeck A/S | Method for manufacture of escitalopram |
EP2397461A1 (en) | 2007-09-11 | 2011-12-21 | H. Lundbeck A/S | Method for the manufacture of escitalopram |
US9297416B2 (en) | 2011-04-29 | 2016-03-29 | Saint-Gobain Performance Plastics Pampus Gmbh | Maintenance-free slide bearing with FEP or PFA in the adhesive layer |
US9782956B2 (en) | 2011-12-28 | 2017-10-10 | Saint-Gobain Performance Plastics Corporation | Polymer coating on substrates using thermal spray techniques |
US9981284B2 (en) | 2011-12-28 | 2018-05-29 | Saint-Gobain Performance Plastics Corporation | Method of forming a laminate |
US10113588B2 (en) | 2012-06-29 | 2018-10-30 | Saint-Gobain Performance Plastics Pampus Gmbh | Slide bearing comprising a primer system as adhesion promoter |
US10563696B2 (en) | 2012-06-29 | 2020-02-18 | Saint-Gobain Performance Plastics Pampus Gmbh | Slide bearing comprising a primer system as adhesion promoter |
US9803690B2 (en) | 2012-09-28 | 2017-10-31 | Saint-Gobain Performance Plastics Pampus Gmbh | Maintenance-free slide bearing with a combined adhesive sliding layer |
DK201500520A1 (en) * | 2015-08-31 | 2016-09-19 | H Lundbeck As | Crystalline forms of (R)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile free base and (S)-4-[4-(dimethylamino)-1-(4'-fluoro-phenyl)-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile free base and of racemic 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-hydroxybutyl]-3-(hydroxyl-methyl)-benzonitrile toluene hemisolvate |
Also Published As
Publication number | Publication date |
---|---|
US7390913B2 (en) | 2008-06-24 |
CA2511143C (en) | 2011-06-28 |
NO331181B1 (en) | 2011-10-24 |
HK1087994A1 (en) | 2006-10-27 |
PL207847B1 (en) | 2011-02-28 |
CY1112937T1 (en) | 2016-04-13 |
US20060020140A1 (en) | 2006-01-26 |
IL169330A0 (en) | 2009-02-11 |
MXPA05006783A (en) | 2005-09-08 |
JP2006511559A (en) | 2006-04-06 |
CA2511143A1 (en) | 2004-07-08 |
NO20053613D0 (en) | 2005-07-25 |
PL377525A1 (en) | 2006-02-06 |
AU2003291960B2 (en) | 2009-11-19 |
EP1581483B1 (en) | 2012-06-06 |
IS2862B (en) | 2013-12-15 |
EP2363389A1 (en) | 2011-09-07 |
NZ540653A (en) | 2008-02-29 |
JP4505335B2 (en) | 2010-07-21 |
NO20053613L (en) | 2005-09-15 |
AU2003291960A1 (en) | 2004-07-14 |
EP1581483A1 (en) | 2005-10-05 |
IS7886A (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5064436B2 (en) | Process for producing racemic citalopram and S- or R-citalopram by separating a mixture of R- and S-citalopram | |
AU2003291960B2 (en) | A process for the preparation of racemic citalopram diol and/or S- or R- citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram | |
ZA200504715B (en) | A process for the preparation of racemic citalopram diol and/or S- or R- citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram | |
AU2002344948B8 (en) | Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram | |
AU2002344948A1 (en) | Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0488 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200504715 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540653 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501133 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003767476 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2511143 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006783 Country of ref document: MX Ref document number: 169330 Country of ref document: IL Ref document number: P20050582A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 377525 Country of ref document: PL Ref document number: 2003291960 Country of ref document: AU Ref document number: 2004561086 Country of ref document: JP Ref document number: 20038A7283X Country of ref document: CN Ref document number: 1364/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057011898 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006020140 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10540300 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05072005 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200501042 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501052 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057011898 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003767476 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317629 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10540300 Country of ref document: US |